BioPharma Credit Past Earnings Performance
Past criteria checks 2/6
BioPharma Credit has been growing earnings at an average annual rate of 11.8%, while the Capital Markets industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 10.1% per year. BioPharma Credit's return on equity is 8.1%, and it has net margins of 79.9%.
Key information
11.8%
Earnings growth rate
9.3%
EPS growth rate
| Capital Markets Industry Growth | 16.3% |
| Revenue growth rate | 10.1% |
| Return on equity | 8.1% |
| Net Margin | 79.9% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How BioPharma Credit makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 136 | 108 | 27 | 0 |
| 30 Sep 23 | 178 | 147 | 31 | 0 |
| 30 Jun 23 | 221 | 185 | 36 | 0 |
| 31 Mar 23 | 219 | 184 | 36 | 0 |
| 31 Dec 22 | 218 | 182 | 36 | 0 |
| 30 Sep 22 | 173 | 146 | 27 | 0 |
| 30 Jun 22 | 128 | 109 | 19 | 0 |
| 31 Mar 22 | 116 | 97 | 19 | 0 |
| 31 Dec 21 | 104 | 85 | 19 | 0 |
| 30 Sep 21 | 109 | 89 | 20 | 0 |
| 30 Jun 21 | 114 | 93 | 21 | 0 |
| 31 Mar 21 | 112 | 91 | 21 | 0 |
| 31 Dec 20 | 110 | 89 | 21 | 0 |
| 30 Sep 20 | 111 | 86 | 25 | 0 |
| 30 Jun 20 | 112 | 83 | 30 | 0 |
| 31 Mar 20 | 132 | 103 | 29 | 0 |
| 31 Dec 19 | 151 | 122 | 29 | 0 |
| 30 Sep 19 | 146 | 119 | 26 | 0 |
| 30 Jun 19 | 142 | 115 | 24 | 0 |
| 31 Mar 19 | 120 | 93 | 23 | 0 |
| 31 Dec 18 | 97 | 70 | 23 | 0 |
| 31 Dec 17 | 34 | 27 | 7 | 0 |
Quality Earnings: BPCR has high quality earnings.
Growing Profit Margin: BPCR's current net profit margins (79.9%) are lower than last year (83.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPCR's earnings have grown by 11.8% per year over the past 5 years.
Accelerating Growth: BPCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BPCR had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Capital Markets industry average (-8.9%).
Return on Equity
High ROE: BPCR's Return on Equity (8.1%) is considered low.